<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This review documents the uses of quantitative MS applied to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) proteomics for biomarker discovery and molecular pathway profiling </plain></SENT>
<SENT sid="1" pm="."><plain>Investigators are adopting various labeling and label-free MS approaches to quantitate differential protein levels in cells, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and plasma/serum </plain></SENT>
<SENT sid="2" pm="."><plain>We comprehensively review recent uses of this technology to examine mouse models of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, their secretomes and subcellular fractions, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patient plasma/serum, and stool samples </plain></SENT>
<SENT sid="3" pm="."><plain>For biomarker discovery these approaches are uncovering proteins with potential diagnostic and prognostic utility, while in vitro cell culture experiments are characterizing proteomic and phosphoproteomic responses to disrupted signaling pathways due to mutations or to inhibition of drugable enzymes </plain></SENT>
</text></document>